Track Sanofi — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Sanofi SNY · Stock Open Sanofi in new tab

48.37 USD
P/E
24.06
EPS
2.01
Yield
9.86%
Safety Score
41
P/B
1.42
ROE
5.72
Beta
0.26
Target Price
54.92 USD
Sanofi logo

Sanofi

🧾 Earnings Recap – Q3 2026

Sanofi’s shares rose 5.6% after earnings, as Q3 sales grew 14.3% to €14.4 billion. The company also reaffirmed its focus on growth through Dupixent’s loss of exclusivity, backed by expanded Regeneron collaboration and planned business development.

  • Sanofi reported Q3 sales of €14.4 billion, up 14.3% year over year.
  • Management named immunology, rare diseases, and vaccines as its strategic focus areas.
  • Sanofi discontinued amlitelimab and itepekimab as part of pipeline optimization.
  • The expanded Regeneron alliance adds access to four immunology compounds; Sanofi aims to launch a long-acting anti-IL-13 for atopic dermatitis ahead of Dupixent biosimilars.
  • Management expects Dupixent’s loss of exclusivity to affect group revenue only moderately, while prioritizing preservation of earnings and cash flow.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 4, 2027
P/E24.06
EPS2.01
Book Value34.11
Price to Book1.42
Debt/Equity27.10
% Insiders0.009%
Growth
Revenue Growth0.16%
Earnings Growth0.09%
Estimates
Forward P/E8.92
Forward EPS5.43
Target Mean Price54.92
Dividend
Dividend Yield9.86%
Annual dividends4.17 USD
Ex-Div. DateMay 4, 2026
Payout117.86%
5y avg Yield3.76%

DCF valuation

Model fair value for Sanofi (SNY)
Result
Sign in to run the valuation for SNY.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
9 analysts · consensus Buy · mean target 54.92 USD (low 45.00, high 63.00) · as of 15 Nov 2026
Low 45.00
Mean 54.92
High 63.00
Price 48.37
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Sanofi Logo Sanofi Analysis (SNY)

France Health Care Official Website Stock

Is Sanofi a good investment? Sanofi (SNY) is currently trading at 48.37 USD. Market analysts have a consensus price target of 54.92 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 24.06. This valuation is generally in line with the broader market.

Earnings Schedule: Sanofi is expected to release its next earnings report on Feb. 4, 2027. The market consensus estimate for Forward EPS is 5.43.

For income investors, Sanofi pays a dividend yield of 9.86%. With a payout ratio of 118%, the dividend appears to be under pressure.

Investor FAQ

Does Sanofi pay a dividend?

Yes, it pays an annual dividend of 4.17 USD (9.86% yield).

What asset class is Sanofi?

Sanofi is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 4, 2027. The company currently has a trailing EPS of 2.01.

Company Profile

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab; and antibody collaboration with Regeneron Pharmaceuticals, Inc. to develop antibodies, such as Dupixent (dupilumab) as treatment for diseases driven by type 2 inflammation. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Exchange Ticker
NMS (United States) SNY
Trades
Dividend Yield
9.86%
5y avg 3.76%
Annual Dividends
4.17USD
Next Ex. Div Date
May 4, 2026
Payout Ratio
117.86%
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2027
2.59 USD
June 2, 2027 (estimated) 2.5925
▸2026
2.42 USD
June 3, 2026 2.4220
▸2025
2.20 USD
June 12, 2025 2.1953
▸2024
2.04 USD
June 6, 2024 2.0370
▸2023
1.90 USD
June 23, 2023 1.9030
▸2022
2.04 USD
June 27, 2022 0.2970
May 31, 2022 1.7470
▸2021
1.93 USD
May 26, 2021 1.9290
▸2020
1.75 USD
May 26, 2020 1.7530
▸2019
1.74 USD
May 31, 2019 1.7390
▸2018
1.86 USD
June 4, 2018 1.8610
▸2017
1.58 USD
June 7, 2017 1.5770
▸2016
1.63 USD
June 1, 2016 1.6300
▸2015
1.62 USD
June 2, 2015 1.6180
▸2014
1.91 USD
June 5, 2014 1.9100
▸2013
11.17 USD
June 5, 2013 9.3100
June 5, 2013 1.8620
▸2012
10.54 USD
May 30, 2012 8.7800
May 30, 2012 1.7560
▸2011
10.93 USD
June 24, 2011 9.1100
June 24, 2011 1.8220
▸2010
82.98 USD
May 17, 2010 81.3500
May 17, 2010 1.6270
▸2009
72.37 USD
April 20, 2009 70.9500
April 20, 2009 1.4190
▸2008
77.01 USD
May 16, 2008 75.5000
May 16, 2008 1.5100
▸2007
58.40 USD
June 4, 2007 57.2500
June 4, 2007 1.1450
▸2006
46.51 USD
June 2, 2006 45.6000
June 2, 2006 0.9120
▸2005
40.75 USD
June 2, 2005 39.9500
June 2, 2005 0.7990
▸2004
31.11 USD
Sept. 27, 2004 1.5000
Sept. 27, 2004 0.0300
April 30, 2004 29.0000
April 30, 2004 0.5800
▸2003
23.56 USD
May 28, 2003 23.1000
May 28, 2003 0.4620
Upcoming Dividends
Name Payment Date Status Amount
Sanofi Jun 03, 2026 2.422 USD
Stock Splits
Split Date Split Ratio to 1
Nov. 17, 2010 10:1
Sept. 30, 2013 5:1
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion